12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cenderitide: Phase I data

Top-line data from a placebo-controlled, U.S. Phase I trial in 58 patients with ADHF showed that subcutaneous infusions of cenderitide met the primary endpoint by achieving undisclosed target PK levels. Additionally, 24-hour subcutaneous infusions of cenderitide were...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >